Protean BioDiagnostics has opened new liquid Biopsy trial in partnership with Epic Sciences for women with recurrent breast cancer in the USA and Canada.
Read MoreDiaceutics announces the establishment of a dedicated Advisory Panel of experts to support and inform the development and rollout of its revolutionary DXRX platform – the world’s first diagnostic network for precision medicine.
Read MoreDiaceutics announces the establishment of a dedicated Advisory Panel of experts to support and inform the development and rollout of its revolutionary DXRX platform – the world’s first diagnostic network for precision medicine.
Read MoreProtean BioDiagnostics is pleased to announce that we are expanding our operations and relocating the head office and laboratories to beautiful new facilities in the Guidewell Center at Medical City in Lake Nona.
Read MoreProtean BioDiagnostics is thrilled to announce that it has now added same-day molecular testing capability to its CAP CLIA certified molecular laboratories. These assays include key biomarker assessments that include evaluation of KRAS, BRAF, and EGFR for presence of activating mutations that guide therapeutic assessment.
Read MoreProtean BioDiagnostics is one of the first labs to make PD-L1 (SP142) testing available for breast cancer patients. Roche’s VENTANA PD-L1 (SP142) Assay was recently approved as a companion diagnostic assay…
Read More